This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Reported reason: Shortage of an active ingredient
Product Information
LISDEXAMFETAMINE 30 MG CAPSULE is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $2.6640 per EA under NDC 00054037125. Its NADAC has been published 153 times since Sep 20, 2023.
FDA first approved this application on Aug 25, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054037125
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA202827FDA Approved
8/25/2023
TE Code
AB
On Market Since
8/25/2023
Pharmacological Classes
Price Statistics
The NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has been published 153 times since Sep 20, 2023, and over the history we have for it it has declined 25.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6640 per EA |
|---|---|
| All-time high | $6.5077 (Apr 10, 2024) |
| All-time low | $2.6640 (Aug 19, 2026) |
| 52-week high | $3.6233 |
| 52-week low | $2.6640 |
| Median price | $3.9018 |
| Average price | $4.0936 |
| Largest weekly change | +59.1% (Jun 19, 2024) |
| Weeks tracked | 153 |
| Tracking since | Sep 20, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LISDEXAMFETAMINE 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 30 MG CAPSULE, manufactured by Hikma Pharmaceuticals USA Inc., is $2.6640 per EA (NDC 00054037125), effective Aug 19, 2026.
How has the price of LISDEXAMFETAMINE 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has declined 25.2%. It has been tracked across 153 weekly CMS publications since Sep 20, 2023.
What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 30 MG CAPSULE?
Since Sep 20, 2023, the NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has ranged from a low of $2.6640 (Aug 19, 2026) to a high of $6.5077 (Apr 10, 2024), with a median of $3.9018 per EA.
Are there cheaper alternatives to LISDEXAMFETAMINE 30 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LISDEXAMFETAMINE 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LISDEXAMFETAMINE 30 MG CAPSULE?
LISDEXAMFETAMINE 30 MG CAPSULE (NDC 00054037125) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Is LISDEXAMFETAMINE 30 MG CAPSULE in shortage?
Yes — NDC 00054037125 is currently listed in FDA's drug shortage database (posted Jul 14, 2023). Reported reason: Shortage of an active ingredient.